Potassium inwardly-rectifying channel subfamily J member 11 (KCNJ11)

Potassium inwardly-rectifying channel subfamily J member 11 (KCNJ11) encodes the Kir6.2 protein, which serves as the pore-forming subunit of the ATP-sensitive potassium (KATP) channel (UniProt Q14654). Primarily expressed in pancreatic beta cells, cardiac muscle, and skeletal muscle, this channel acts as a metabolic sensor by coupling the cell's metabolic state, specifically the ATP/ADP ratio, to its membrane potential (NCBI Gene 3767). In the pancreas, an increase in intracellular ATP leads to the closure of KCNJ11-containing channels, triggering membrane depolarization, calcium influx, and subsequent insulin secretion (PubMed PMID: 15133175). Mutations in the KCNJ11 gene are critically linked to various glycemic disorders, including permanent neonatal diabetes mellitus and congenital hyperinsulinism (NCBI Gene 3767). Pharmacologically, KCNJ11 is a major target for sulfonylureas and meglitinides, which promote insulin release by inducing channel closure to treat type 2 diabetes (StatPearls, Sulfonylureas). Conversely, potassium channel openers like diazoxide are used to treat hyperinsulinism by keeping the channel open and preventing excessive insulin release.

Other names

Kir6.2Inward rectifier K+ channel Kir6.2ATP-sensitive inward rectifier potassium channel 11BIRHHF2TNDM3PHHIMODY13

Drugs like sulfonylureas and meglitinides bind to the associated regulatory subunit (SUR1) to induce closure of the KCNJ11 pore, leading to beta-cell depolarization and insulin release; conversely, activators like diazoxide stabilize the open state to inhibit insulin secretion.